Sign in or create an account to add this stock to your watchlist.
About NeoGenomics (NASDAQ:NEO)
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Industry, Sector and Symbol
Industry Testing laboratories
Trailing P/E Ratio191.00
Forward P/E Ratio114.60
Sales & Book Value
Annual Sales$258.61 million
Price / Sales3.57
Cash Flow$0.4825 per share
Price / Cash23.75
Book Value$2.14 per share
Price / Book5.36
EPS (Most Recent Fiscal Year)$0.06
Return on Equity3.19%
Return on Assets1.58%
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics (NASDAQ:NEO) released its quarterly earnings data on Tuesday, May, 1st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. The medical research company had revenue of $63.40 million for the quarter, compared to analysts' expectations of $62.31 million. NeoGenomics had a positive return on equity of 3.19% and a negative net margin of 0.86%. NeoGenomics's quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.03 earnings per share. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $0.15-$0.20 for the period, compared to the Thomson Reuters consensus estimate of $0.17. The company issued revenue guidance of $260-$272 million, compared to the consensus revenue estimate of $266.42 million.
What price target have analysts set for NEO?
8 brokers have issued 1-year target prices for NeoGenomics' shares. Their forecasts range from $9.00 to $24.00. On average, they anticipate NeoGenomics' share price to reach $16.50 in the next twelve months. View Analyst Ratings for NeoGenomics.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include Blueprint Medicines (BPMC), Immunomedics (IMMU), Abcam (ABCZY), Tenet Healthcare (THC), Enerplus (ERF), Healthscope (HSO), BTG (BTGGF), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Foundation Medicine (FMI), Teladoc (TDOC), UDG Healthcare (UDHCF), arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP) and Hikma Pharmaceuticals (HKMPY).
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
- Mr. Steven C. Jones, Exec. VP & Director (Age 55)
- Dr. Maher Albitar, Sr. VP, Chief Medical Officer and Director of R&D (Age 63)
- Dr. Steven G. Brodie, VP of Operations (Age 57)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)
Has NeoGenomics been receiving favorable news coverage?
News stories about NEO stock have trended somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NeoGenomics earned a coverage optimism score of 0.14 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 45.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (5.90%), BlackRock Inc. (4.92%), Russell Investments Group Ltd. (3.32%), Artisan Partners Limited Partnership (2.68%), Granite Investment Partners LLC (2.11%) and Franklin Resources Inc. (1.93%). Company insiders that own NeoGenomics stock include Alison L Hannah, Jennifer Balliet, Maher Albitar, Oort Douglas M Van, Steven A Ross and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.
Which major investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Artisan Partners Limited Partnership, Penn Capital Management Co. Inc., Blair William & Co. IL, C WorldWide Group Holding A S, New York State Common Retirement Fund, Atlantic Trust Group LLC and Allianz Asset Management GmbH. Company insiders that have sold NeoGenomics company stock in the last year include Jennifer Balliet and Steven A Ross. View Insider Buying and Selling for NeoGenomics.
Which major investors are buying NeoGenomics stock?
NEO stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Franklin Resources Inc., Gabelli Funds LLC, RMB Capital Management LLC, Gamco Investors INC. ET AL, Citadel Advisors LLC, Trexquant Investment LP and Cortina Asset Management LLC. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $11.46.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $914.20 million and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NEO)MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
NeoGenomics (NASDAQ:NEO) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for NeoGenomics in the last 12 months. Their average twelve-month price target is $16.50, suggesting that the stock has a possible upside of 43.98%. The high price target for NEO is $24.00 and the low price target for NEO is $9.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.86||2.71||2.75|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$16.50||$17.2857||$15.8333||$10.3333|
|Price Target Upside: ||43.98% upside||103.60% upside||81.57% upside||28.84% upside|
NeoGenomics (NASDAQ:NEO) Consensus Price Target History
NeoGenomics (NASDAQ:NEO) Analyst Ratings History
(Data available from 5/23/2016 forward)
NeoGenomics (NASDAQ:NEO) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
NeoGenomics (NASDAQ NEO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 83.66%
NeoGenomics (NASDAQ NEO) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/15/2018||Jennifer Balliet||VP||Sell||13,000||$11.24||$146,120.00||13,000|| |
|5/10/2018||Steven A Ross||Insider||Sell||81,999||$10.78||$883,949.22||4,500|| |
|7/27/2017||Alison L Hannah||Director||Buy||20,000||$9.19||$183,800.00||38,782|| |
|6/22/2017||Jennifer Balliet||VP||Sell||10,723||$8.49||$91,038.27|| |
|6/5/2017||Steven A Ross||Insider||Sell||70,833||$7.76||$549,664.08||4,500|| |
|5/26/2017||Jennifer Balliet||VP||Sell||3,334||$7.50||$25,005.00||10,049|| |
|3/20/2017||Steven G Brodie||Insider||Sell||50,000||$7.93||$396,500.00||49,403|| |
|9/23/2016||Maher Albitar||Insider||Sell||2,800||$8.40||$23,520.00|| |
|9/20/2016||Maher Albitar||Insider||Sell||105,300||$8.20||$863,460.00||105,300|| |
|9/12/2016||Maher Albitar||Insider||Sell||60,075||$8.23||$494,417.25||165,375|| |
|8/19/2016||Maher Albitar||Insider||Sell||370,000||$8.23||$3,045,100.00||263,492|| |
|5/27/2016||Oort Douglas M Van||CEO||Sell||481,387||$8.73||$4,202,508.51||1,675,000|| |
|5/18/2016||Steven A Ross||Insider||Sell||18,000||$8.50||$153,000.00||4,500|| |
|5/9/2016||Steven A Ross||Insider||Sell||15,000||$8.22||$123,300.00||4,500|| |
|5/2/2016||Steven C Jones||VP||Sell||177,745||$8.21||$1,459,286.45||266,251|| |
|4/29/2016||Steven A Ross||Insider||Sell||112,500||$8.11||$912,375.00||117,000|| |
|3/11/2016||George Cardoza||CFO||Sell||32,000||$6.83||$218,560.00||221,089|| |
|3/9/2016||Oort Douglas M Van||CEO||Sell||450,000||$7.10||$3,195,000.00||2,125,000|| |
|3/3/2016||Alison L Hannah||Director||Buy||10,000||$6.90||$69,000.00||11,560|| |
|12/7/2015||Lynn A Tetrault||Director||Buy||3,500||$7.72||$27,020.00||5,060|| |
|12/3/2015||Robert J Shovlin||COO||Buy||6,550||$7.75||$50,762.50||6,550|| |
|11/27/2015||Steven C Jones||VP||Sell||385,000||$8.09||$3,114,650.00||286,251|| |
|11/2/2015||Bruce K Crowther||Director||Buy||6,400||$7.81||$49,984.00|| |
|12/19/2014||Robert H Horel||VP||Sell||32,389||$4.21||$136,357.69|| |
|12/18/2014||Robert H Horel||VP||Sell||62,893||$4.20||$264,150.60|| |
|12/4/2014||Michael T Dent||Director||Sell||11,800||$4.50||$53,100.00|| |
|11/26/2014||George Cardoza||CFO||Sell||60,000||$4.28||$256,800.00|| |
|11/21/2014||Michael T Dent||Director||Sell||33,200||$4.51||$149,732.00|| |
|5/22/2014||Robert P Gasparini||Insider||Sell||100,000||$3.49||$349,000.00|| |
|5/19/2014||Robert Gasparini||Insider||Sell||10,000||$3.65||$36,500.00||8,439|| |
|3/28/2014||Maher Albitar||Insider||Buy||14,492||$3.51||$50,866.92|| |
|3/5/2014||Michael T Dent||Director||Sell||300,000||$3.00||$900,000.00|| |
|12/11/2013||Robert P Gasparini||Insider||Sell||20,100||$3.70||$74,370.00|| |
|12/9/2013||George Cardoza||CFO||Sell||20,000||$3.66||$73,200.00|| |
|12/5/2013||Robert P Gasparini||Insider||Sell||32,996||$3.67||$121,095.32|| |
|12/3/2013||Robert P Gasparini||Insider||Sell||32,146||$3.67||$117,975.82|| |
|11/25/2013||Steven C Jones||VP||Sell||112,969||$3.58||$404,429.02|| |
|4/30/2013||Steven C Jones||Director||Sell||100,000||$3.71||$371,000.00|| |
NeoGenomics (NASDAQ NEO) News Headlines
|Form 4 NEOGENOMICS INC For: May 15 Filed by: BALLIET JENNIFER|
www.streetinsider.com - May 17 at 5:34 PM
|NeoGenomics (NEO) Upgraded to "Strong-Buy" at ValuEngine|
www.americanbankingnews.com - May 17 at 5:33 PM
|NeoGenomics (NEO) VP Jennifer Balliet Sells 13,000 Shares|
www.americanbankingnews.com - May 17 at 4:45 PM
|NeoGenomics (NEO) Expected to Post Quarterly Sales of $65.57 Million|
www.americanbankingnews.com - May 14 at 1:52 AM
|Zacks: Analysts Anticipate NeoGenomics (NEO) Will Announce Earnings of $0.04 Per Share|
www.americanbankingnews.com - May 12 at 11:12 PM
|NeoGenomics (NEO) Insider Steven A. Ross Sells 81,999 Shares|
www.americanbankingnews.com - May 10 at 7:37 PM
|NeoGenomics (NEO) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - May 6 at 8:01 PM
|First Analysis Comments on NeoGenomics' Q1 2019 Earnings (NEO)|
www.americanbankingnews.com - May 3 at 9:30 AM
|Edited Transcript of NEO earnings conference call or presentation 1-May-18 12:30pm GMT|
finance.yahoo.com - May 3 at 8:45 AM
|NeoGenomics (NEO) Tops Q1 EPS by 1c, Beats on Revenues; Offers FY18 EPS/Revenue Outlook|
www.streetinsider.com - May 2 at 5:08 PM
www.streetinsider.com - May 2 at 8:50 AM
|NeoGenomics (NEO) Rating Lowered to Hold at First Analysis|
www.americanbankingnews.com - May 2 at 7:26 AM
|NeoGenomics' (NEO) CEO Doug VanOort on Q1 2018 Results - Earnings Call Transcript|
seekingalpha.com - May 1 at 4:53 PM
|NeoGenomics: 1Q Earnings Snapshot|
finance.yahoo.com - May 1 at 4:53 PM
|NeoGenomics (NEO) Releases FY18 Earnings Guidance|
www.americanbankingnews.com - May 1 at 10:10 AM
|NeoGenomics (NEO) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS|
www.americanbankingnews.com - May 1 at 9:54 AM
|NeoGenomics (NEO) Lifted to "Strong-Buy" at BidaskClub|
www.americanbankingnews.com - April 28 at 7:40 AM
|Analyzing NeoGenomics (NEO) & Intertek (IKTSY)|
www.americanbankingnews.com - April 27 at 7:10 PM
| Analysts Anticipate NeoGenomics (NEO) Will Announce Quarterly Sales of $63.69 Million|
www.americanbankingnews.com - April 27 at 3:32 AM
|NeoGenomics (NEO) & Intertek (IKTSY) Financial Contrast|
www.americanbankingnews.com - April 25 at 9:26 PM
| Brokerages Expect NeoGenomics (NEO) to Post $0.03 EPS|
www.americanbankingnews.com - April 25 at 11:28 AM
|Equities Analysts Offer Predictions for NeoGenomics' Q4 2018 Earnings (NEO)|
www.americanbankingnews.com - April 25 at 9:49 AM
|NeoGenomics (NEO) Scheduled to Post Quarterly Earnings on Tuesday|
www.americanbankingnews.com - April 24 at 6:52 AM
|NeoGenomics (NEO) versus Intertek Group (IKTSY) Critical Analysis|
www.americanbankingnews.com - April 18 at 1:34 PM
|NeoGenomics (NEO) Upgraded by BidaskClub to Buy|
www.americanbankingnews.com - April 18 at 9:51 AM
|NeoGenomics (NEO) Upgraded at BidaskClub|
www.americanbankingnews.com - April 17 at 1:54 PM
|NeoGenomics (NEO) Upgraded by ValuEngine to Buy|
www.americanbankingnews.com - April 17 at 10:29 AM
|BTIG Upgrades Neogenomics (NEO) to Buy|
www.streetinsider.com - April 16 at 8:46 AM
|NeoGenomics (NEO) Rating Increased to Buy at BTIG Research|
www.americanbankingnews.com - April 16 at 7:39 AM
|NeoGenomics, Inc. (NEO) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - April 11 at 7:35 PM
|Contrasting Intertek Group (IKTSY) and NeoGenomics (NEO)|
www.americanbankingnews.com - April 10 at 9:21 AM
| Analysts Anticipate NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million|
www.americanbankingnews.com - April 10 at 3:30 AM
| Analysts Anticipate NeoGenomics, Inc. (NEO) to Post $0.03 EPS|
www.americanbankingnews.com - April 8 at 1:22 PM
|NeoGenomics (NEO) Cut to "Buy" at BidaskClub|
www.americanbankingnews.com - April 6 at 7:03 PM
|NeoGenomics (NEO) Upgraded to "Hold" by Zacks Investment Research|
www.americanbankingnews.com - April 4 at 11:26 PM
|Head to Head Review: NeoGenomics (NEO) & Intertek Group (IKTSY)|
www.americanbankingnews.com - April 3 at 11:39 PM
|NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018|
feeds.benzinga.com - April 2 at 5:46 PM
|Analyzing Intertek Group (IKTSY) & NeoGenomics (NEO)|
www.americanbankingnews.com - April 2 at 9:14 AM
|NeoGenomics (NEO) versus Intertek Group (IKTSY) Head to Head Comparison|
www.americanbankingnews.com - April 2 at 1:32 AM
|Reviewing NeoGenomics (NEO) and Its Rivals|
www.americanbankingnews.com - March 28 at 5:28 PM
|NeoGenomics (NEO) Rating Lowered to Sell at BidaskClub|
www.americanbankingnews.com - March 27 at 3:28 PM
|NeoGenomics (NEO) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - March 25 at 2:34 PM
|NeoGenomics (NEO) Lifted to Hold at Zacks Investment Research|
www.americanbankingnews.com - March 24 at 3:56 PM
| Analysts Expect NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million|
www.americanbankingnews.com - March 24 at 7:54 AM
|NeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.03 Per Share|
www.americanbankingnews.com - March 22 at 1:28 PM
|Global Cancer/Tumor Profiling Market Report 2017 Analysis & Forecasts 2013-2023 - Rising Utility of Biomarkers in ... - PR Newswire (press release)|
www.prnewswire.com - March 20 at 4:51 PM
|NeoGenomics Announces Executive Appointments|
finance.yahoo.com - March 20 at 9:03 AM
|Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement|
finance.yahoo.com - March 19 at 8:58 AM
|NeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - March 17 at 7:38 PM
|NeoGenomics (NEO) Given New $24.00 Price Target at Canaccord Genuity|
www.americanbankingnews.com - March 13 at 5:17 PM
NeoGenomics (NASDAQ:NEO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NeoGenomics (NASDAQ:NEO) Income Statement, Balance Sheet and Cash Flow Statement
NeoGenomics (NASDAQ NEO) Stock Chart for Wednesday, May, 23, 2018